#USA #New York #Class Action #Pacira BioSciences #PCRX

Important Notice for Pacira BioSciences, Inc. Investors

Pacira BioSciences, Inc. (NASDAQ: PCRX) is currently facing a significant class action lawsuit that shareholders need to be aware of. The Gross Law Firm has recently issued a reminder about this lawsuit, which has drawn attention due to its potential implications for the company's future and its investors' stakes.

Background of the Class Action

The class action involves shareholders who purchased Pacira stocks between August 2, 2023, and August 8, 2024. Recently, the company disclosed unfortunate news regarding its U.S. Patent No. 11,033,495, which directly affects Exparel, the primary revenue source for the firm. Following a court ruling that invalidated this patent, serious concerns were raised regarding the integrity of Pacira's other patents, potentially leading to increased competition from generic methods and rising litigation costs.

On August 9, 2024, after the adverse ruling, Pacira’s stock price plummeted from a closing price of $22.36 to as low as $11.70 in a single day, representing a staggering loss of over 47%. This drastic decline underscores the gravity of the ongoing situation and the importance for shareholders to consider their options regarding potential recovery.

Who Is Affected?

Investors who purchased Pacira shares during the specified class period are strongly encouraged to reach out to The Gross Law Firm. Although being appointed as a lead plaintiff is not a requisite to join this lawsuit, the firm highly recommends registering as soon as possible to ensure shareholders are in a position to reclaim their losses.

Key Dates and Information

• - Lead Plaintiff Deadline: March 14, 2025

This deadline signifies the final date for shareholders to register their interest in seeking lead plaintiff status, making it imperative to act promptly if you haven't done so already.

• - Registration: To participate in the action, interested shareholders can complete the registration process through this link: Register Here

In addition to registering, participants will be provided with portfolio monitoring tools to receive updates on the case's progress, ensuring they remain informed throughout the proceedings.

Why Choose The Gross Law Firm?

The Gross Law Firm possesses extensive experience in class action lawsuits and is dedicated to defending investor rights. Their mission focuses on addressing the impact of fraud, deceit, and non-compliance by public companies that results in financial loss to shareholders. Their reputation in the legal community as a leading class action firm reinforces their commitment to investor advocacy and corporate accountability.

As shareholders navigate this challenging phase, it’s critical to remain aware of their rights and options. In uncertain times like these, proactive management of one's investments becomes essential.

How to Contact The Gross Law Firm

For more detailed conversations or inquiries regarding the lawsuit, investors can connect with The Gross Law Firm directly:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

In light of these developments, Pacira investors are advised to stay informed and take necessary actions to safeguard their investments. Understand your options and do not hesitate to reach out to legal professionals to explore potential pathways to recovery.